PharmaCorp Manufacturing Solutions

Global leader in pharmaceutical development and manufacturing services

45+

Years in Industry

Global Facilities

600+

Regulatory Filings

An Exclusive Conversation with Dr. James Mitchell

What sets PharmaCorp apart in today’s competitive CDMO landscape?

Our differentiation comes from true end-to-end integration. Unlike competitors who outsource key capabilities, we’ve built our platform organically. This ensures seamless technology transfer, consistent quality systems, and a unified culture across all sites.

How are you preparing for the next wave of therapeutic modalities?<br />

We’re making significant investments in cell and gene therapy, mRNA, and advanced biologics. Our $500 million expansion in North Carolina will house next-generation manufacturing suites designed for flexibility. We’re also investing heavily in digital transformation—AI-powered process optimization, digital twins, and predictive quality systems.

What advice would you give to emerging pharma companies selecting a CDMO partner?

Look beyond capacity and pricing. Evaluate the partnership culture. Ask about their experience with regulatory agencies—how many first-cycle approvals? Understand their technology transfer process and ask for references from companies at your stage. The right partner will feel like an extension of your team, not just a vendor.

Where do you see the industry heading in the next decade?

Personalized medicine will fundamentally reshape manufacturing. We’ll see smaller batch sizes, more complex supply chains, and greater demand for flexibility. CDMOs that can offer platform technologies for rapid product changeover while maintaining quality and compliance will thrive. Sustainability will also become a key differentiator.

About

PharmaCorp Manufacturing Solutions stands as one of the world’s most comprehensive contract development and manufacturing organizations. With over 45 years of pharmaceutical expertise, we offer fully integrated, end-to-end solutions spanning drug substance and drug product development through commercial manufacturing at scale.

What Makes Them Unique

True end-to-end integrated services from drug substance through commercial manufacturing
Global manufacturing footprint with facilities on 4 continents

Strong financial stability and long-term investment commitment

Comprehensive technology portfolio spanning small molecules, biologics, and cell/gene therapy

Virtual Facility Tour

Take an exclusive inside look at state-of-the-art manufacturing facilities and quality control laboratories.

Plans for the Future

2025 EXPANSION

New Biologics Campus

$500M investment in next-generation biologics manufacturing facility with 40,000L capacity.

TECHNOLOGY

Continuous Manufacturing

Industry 4.0 integration with AI-powered process optimization across all facilities

Frequently Asked Questions

What is the typical project timeline from development to commercial manufacturing?

Our integrated approach typically reduces time-to-market by 20-30% compared to multi-vendor strategies. For small molecules, expect 18-24 months from development through commercial validation. Biologics programs typically run 24-36 months.

What are your minimum batch size requirements?

We offer flexible manufacturing scales to accommodate companies of all sizes. For oral solid dose, we can start from 10kg development batches up to multi-ton commercial campaigns.

Do you offer dedicated manufacturing suites?

Yes, we offer both shared and dedicated suite options depending on program requirements. Dedicated suites are recommended for products with complex containment needs.

What regulatory support do you provide?

Our regulatory affairs team includes 200+ professionals supporting global submissions. We provide comprehensive support including CMC documentation, IND/NDA/BLA filings, and EU/international dossiers.

How do you handle intellectual property protection?

IP protection is paramount. We maintain strict confidentiality protocols, segregated production areas, controlled access to documentation, and robust IT security.